These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Marzano AV; Tourlaki A; Alessi E; Caputo R Clin Exp Dermatol; 2008 Mar; 33(2):156-9. PubMed ID: 18021268 [TBL] [Abstract][Full Text] [Related]
9. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Shareef MS; Munro LR; Owen RG; Highet AS Clin Exp Dermatol; 2012 Mar; 37(2):146-8. PubMed ID: 22103549 [TBL] [Abstract][Full Text] [Related]
10. The dilemma of treating pyoderma gangrenosum associated with monoclonal gammopathy of undetermined significance. Machan A; Azendour H; Frikh R; Hjira N; Boui M Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621712 [TBL] [Abstract][Full Text] [Related]
11. Peripheral ulcerative keratitis--an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet's syndrome with an excellent response to cyclosporine therapy. Wilson DM; John GR; Callen JP J Am Acad Dermatol; 1999 Feb; 40(2 Pt 2):331-4. PubMed ID: 10025862 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy in the setting of Pyoderma gangrenosum. Saeidi V; Garimella V; Shaji K; Wetter DA; Davis MDP; Todd A; Dutz J; Alavi A Arch Dermatol Res; 2024 May; 316(6):268. PubMed ID: 38795175 [TBL] [Abstract][Full Text] [Related]
13. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa. Fischer AH; Jourabchi N; Khalifian S; Lazarus GS Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180 [TBL] [Abstract][Full Text] [Related]
14. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009 [TBL] [Abstract][Full Text] [Related]
15. Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment. Molinelli E; Brisigotti V; Paolinelli M; Offidani A Curr Pharm Biotechnol; 2021; 22(1):46-58. PubMed ID: 32359335 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report. Noto R; Kamiura N; Ono Y; Tabata S; Hara S; Yokoi H; Yoshimoto A; Yanagita M BMC Nephrol; 2017 Apr; 18(1):127. PubMed ID: 28385149 [TBL] [Abstract][Full Text] [Related]
17. Subcorneal pustulosis and Pyoderma gangrenosum associated with a biclonal gammopathy. Puechguiral-Renaud I; Carpentier O; Piette F; Delaporte E Eur J Dermatol; 2006; 16(6):687-90. PubMed ID: 17229613 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report. Baglieri F; Scuderi G Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408 [TBL] [Abstract][Full Text] [Related]